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Outcomes Study Cognitive Functioning-Revised [MOS COG-R]; PHQ-9, Patient Global 
Impression of Severity [PGIS] and Change [PGIC]; SF-36 Health Survey [SF-36], Lam 
Employment Absence and Productivity Scale [LEAPS], Sheehan Disability Scale 
[SDS] and Work Productivity and Activity Impairment: Specific Health Problem 
[WPAI:SHP]. Results: The study population consisted of 855 subjects at baseline 
(418 US and 437 UK), with MDD patients representing 49% of the sample in each 
country; 169 and 153 MDD patients were invited for the follow-up in the US and 
UK, respectively. Internal consistency was high for the total scale and for the four 
proposed subscales (Attention, Retrospective memory, Prospective memory, and 
Planning), with Cronbach’s alpha ranging from 0.81 to 0.96. Convergent validity was 
supported by strong correlations with other measures of cognitive functioning (0.8 
Pearson’s coefficient) and moderate correlations with several construct measures 
known to be associated with cognitive functioning, including health-related quality 
of life, productivity at work, and other functional impairment (Pearson’s coefficients 
ranging from 0.3 to 0.6), and by substantial differences in scores in subgroups known 
to differ in cognitive functioning impairment. The PDQ-D was also responsive to 
changes in depression symptom severity. Confirmatory factor analyses supported 
the scoring of a global scale for perceived cognitive functioning. ConClusions: The 
PDQ-D is a reliable, valid and responsive instrument for assessing MDD patients’ 
perception of deficits related to cognitive functioning.
RESEARCH POSTER PRESENTATIONS – SESSION I 
DISEASE-SPECIFIC STUDIES
INDIvIDUAl’S HEAlTH – Clinical Outcomes Studies
PIH1
MOTHERS’ OwN MIlk FOR THE FEEDINg OF PRETERM INFANTS: A SySTEMATIC 
lITERATURE REvIEw
Garcia-Stewart S., Mitchell S.A.
Abacus International, Bicester, UK
objeCtives: To conduct a systematic review to examine the incremental benefits 
of mothers’ own milk (MM), with or without fortification, compared with donor 
milk (DM) and/or preterm formula (PF) for the nutritional support of preterm 
infants both in the neonatal intensive care unit (NICU) and following hospital dis-
charge. Methods: English-language studies published post-1990 were identified 
from electronic databases (Medline, EMBASE and Cochrane Library) and confer-
ence proceedings. Eligible studies enrolled infants with mean gestational age less 
than 35 weeks with no restriction on geographical location. Results: Thirty-three 
unique studies met eligibility criteria: United States (n= 12), Canada (n= 2), Australia 
(n= 2), Mexico (n= 1), Israel (n= 2), Europe (n= 13) or multinational (n= 1). There was 
a paucity of both RCT data (n= 7) and studies which reported exclusive use of MM 
feeding (n= 3). In addition, there was considerable heterogeneity between studies 
with regard to study design, duration of follow up and amounts of MM ingested, and 
a robust meta-analysis was therefore not feasible. However, a significant beneficial 
effect for MM over DM and/or PF for the incidence of sepsis, necrotizing enterocolitis 
(NEC) and longer-term neurodevelopment was reported in a number of individual 
studies. With regard to anthropomorphic outcomes of body weight, length and 
head circumference, there was no clear consensus on the effect of feeding regi-
men. Sixteen studies reported the relationship between the dose of MM received 
and outcomes; increased MM dosages in the feeding regimen were associated with 
significantly lower rates of sepsis, NEC, and hospital readmissions, reduced NICU 
costs, and improved neurodevelopment. ConClusions: Exclusive or high-dose 
MM with or without fortification is associated with short- and long-term beneficial 
effects in preterm infants. These results confirm MM to be the optimal nutrition for 
preterm infants and stress the importance of developing comprehensive strategies 
to overcome the challenges of providing MM and improving breastfeeding rates in 
preterm infants in the NICU.
PIH2
UTERINE-SPARINg SURgICAl TREATMENT MODAlITIES IN wOMEN wITH 
UTERINE FIbROIDS: A SySTEMATIC REvIEw AND INDIRECT TREATMENT 
COMPARISON
Panagiotopoulou N.1, Nethra S.1, Karabis A.2, Ahmad G.1, Burls A.3
1Pennine Acute Hospitals NHS Trust, Manchester, UK, 2Mapi – HEOR & Strategic Market Access, 
Houten, The Netherlands, 3City University London, London, UK
objeCtives: To evaluate the safety and effectiveness of conservative sur-
gical treatments for uterine fibroids in women who wish to preserve their 
uterus. Methods: A systematic literature search of electronic databases 
(MEDLINE, EMBASE, CENTRAL) and grey literature up to October 2012 identified 5 
RCTs (436 patients): 2 comparing uterine artery embolization (UAE) with myomec-
tomy (MYO) and 3 comparing UAE with laparoscopic uterine artery occlusion 
(LUAO). Primary outcome measures included patients’ satisfaction, re-intervention 
and ovarian failure rate. Secondary outcomes were clinical failure, hysterectomy 
and complication rates, hospitalization and recovery times, pregnancy rate, preg-
nancy complications and live-birth rate. Standard and network meta-analysis 
were performed on relevant outcomes. Results: Of the three most popular 
uterine-sparing surgical treatments for fibroids, network meta-analysis showed 
that MYO and UAE resulted in higher rates of patient satisfaction and lower rates 
of clinical failure than LUAO in the first year after treatment [OR 2.56, 95%CrI 0.56- 
11.75, P(better)= 11% and 2.7, 95%CrI 1.1- 7.14, P(better)= 1%; 0.29, 95%CrI 0.06- 1.46, 
P(better)= 7% and 0.37, 95%CrI 0.13- 0.93, P(better)= 2% respectively]. Moreover, MYO 
resulted in lower re-intervention and hysterectomy rates than UAE and LUAO [0.08, 
95%CrI 0.02- 0.27, P(better)< 1%, 0.08, 95%CrI 0.01- 0.37 P(better)< 1%); 0.16, 95%CrI 
0.01-0.85 P(better)= 2%, 0.15 95%CrI 0- 8.74 P(better)= 16% respectively] even though 
the later techniques had an advantage over MYO due to shorter hospitalization 
and quicker recovery. There was no evidence of convincing difference between the 
three techniques in the number of women experiencing ovarian failure, minor or 
major complications. However, MYO may lead to better conception outcomes in 
absolute error was on average 0.15 but was considerably high (> 0.34) if the observed 
EQ-5D value was below 0.5. Sensitivity analysis revealed that different EQ-5D value 
sets resulted in different algorithms but similar predicting ability. ConClusions: 
Our study showed that there are conceptual differences between the CCQ and EQ-5D 
and mapping should be considered as second-best option compared to directly 
collected EQ-5D data. Furthermore, the mapping performance seems to depend on 
the severity of the study population.
Ql2
MEASURINg PATIENT-RElEvANT TREATMENT bENEFIT IN DERMATOlOgy – 
DEvElOPMENT AND vAlIDATION OF THE SHORT QUESTIONNAIRE “PATIENT 
bENEFIT INDEx 2.0”
Blome C.1, von Usslar K.1, Augustin M.2
1University Medical Center Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
objeCtives: Evidence on patient-relevant treatment benefit is the main criterion 
for reimbursement decisions in many European countries. Usually, an increase of 
quality of life (QoL) during treatment is used as benefit indicator. The Patient Benefit 
Index (PBI) method, in contrast, evaluates benefit retrospectively: Before treatment, 
patients rate importance of treatment goals; after treatment, they rate goal achieve-
ment. This prevents any bias due to response shift which has repeatedly been found 
in pre-post QoL assessment. Here, we developed a short PBI version (“PBI 2.0”) appli-
cable to different skin diseases. Methods: Treatment goal items for the PBI 2.0 
were developed based on nine validated disease-specific PBI versions. Items were 
tested for content, completeness, and comprehensiveness in qualitative interviews 
with n= 16 patients with atopic dermatitis, leg ulcers, psoriasis, and vitiligo. Items 
were revised on basis of patient feedback. The PBI 2.0 was tested for convergent 
validity, completeness, and congruence with disease-specific PBI versions in a cross-
sectional study on n= 379 patients with the above-mentioned diagnoses. Results: 
The 74 disease-specific items could be condensed to 15 pilot items. Based on the 
qualitative interviews, we could reduce to 12 items. The majority of patients rated 
the PBI 2.0 to be comprehensible (93-98%, depending on diagnosis group), readable 
(94-100%), easy to answer throughout (78-90%), and complete (65-88%). Treatment 
goals mentioned as missing mostly concerned goals unrelated to benefit of medical 
treatment (e.g. information on the disease). The percentage of missing values ranged 
from 0.0% to 2.9%. PBI 2.0 preference-weighted global scores correlated significantly 
with QoL as measured with Dermatology Life Quality Index and EQ-5D (r= 0.19 to 
0.58). Convergent validity of the PBI 2.0 and the respective – about twice as long – 
disease-specific versions were equal, except for the vitiligo version. ConClusions: 
The PBI 2.0 is a qualitatively and quantitatively validated short questionnaire on 
patient-relevant treatment benefit in dermatology.
Ql3
THE MEASUREMENT OF HEAlTH-RElATED QUAlITy OF lIFE: gERMAN 
FINDINgS FROM THE MUlTI-INSTRUMENT COMPARISON (MIC) STUDy
Schlander M.1, Khan M.A.2, Iezzi A.2, Maxwell A.2, Richardson J.2
1University of Heidelberg, Wiesbaden, Germany, 2Monash University, Melbourne, Australia
objeCtives: Different multi-attribute utility (MAU) instruments are known to pro-
duce different values for “utility” and measure different constructs, despite the 
common label “utility”. To date, the Multi-Instrument Comparison (MIC) project has 
been the largest comparative study of health and well-being instruments under-
taken worldwide. Here we report the first results from the German branch of the 
study. Methods: A total of 1269 German respondents (either healthy or suffering 
from defined chronic disorders, i.e., asthma, arthritis, cancer, depression, diabetes, 
hearing loss, heart disease) were recruited and participated in the study, completing 
various MAU instruments, including the EQ-5D, SF-6D, HUI3, 15D, QWB, AQoL(-4D 
and-8D). Cross-validation tests drew heavily on correlation. Preliminary findings, 
based upon Pearson correlation coefficients (indicating the extent to which changes 
in one variable correspond with changes in another), showed low correlations 
between measures of utility and measures of subjective well-being. While prefer-
ences might differ from subjective well-being, their correlation might be higher. 
Hence, a better measure should be intraclass correlation (ICC). Results: Intraclass 
correlations between MAU instruments ranged from to 0.8 (HUI3 vs. AQoL-8D) to 
0.4 (AQoL-4D vs. 15D). Linear regression results, reflecting the comparative perfor-
mance of the various MAU instruments with regard to changes in measured utilities 
(as applied in standard cost utility analysis), and detailed results including pair-
wise comparisons of instruments, especially as to sensitivity to changes in a given 
dimension, will be presented. ConClusions: A major conclusion of the present 
study is that, despite some similarity in the mean scores, the instruments tested are 
dissimilar with regard to virtually all other criteria used to compare them. In effect, 
each instrument appears to measure a different construct of “health”. Implications 
for the presumably “generic” measurement of “utility” may be far reaching and will 
be discussed.
Ql4
PSyCHOMETRIC vAlIDATION OF PERCEIvED DEFICITS QUESTIONNAIRE – 
DEPRESSION (PDQ-D) IN PATIENTS wITH MAjOR DEPRESSIvE DISORDER (MDD)
Lam R.W.1, Saragoussi D.2, Danchenko N.3, Rive B.4, Lamy F.X.5, Brevig T.6
1University of British Columbia, Vancouver, BC, Canada, 2Lundbeck SAS, ISSY LES MOULINEAUX 
CEDEX, France, 3Lundbeck SAS, Issy-les-Moulineaux, France, 4Lundbeck S.A.S., Issy-Les 
Moulineaux, France, 5Lundbeck S.A.S., Issy-les-Moulineaux, France, 6H. Lundbeck A/S, Valby, 
Denmark
objeCtives: The Perceived Deficits Questionnaire (PDQ) provides a self-report 
measure of cognitive dysfunction. The current work aims at assessing the psycho-
metric properties of the PDQ adapted for MDD (PDQ-D). Methods: A non-inter-
ventional, online panel survey with baseline assessment and 6-week follow-up 
of US and UK residents (aged ≥ 18 years) with and without MDD [diagnosed with 
depression by a physician and current Patient Health Questionnaire-9 (PHQ-9) 
score ≥ 10]. In addition to PDQ-D, the following instruments were included: Medical 
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of 0.5 (95%CI: 0.3-0.8) for DRSP/estradiol vs. other occHRT. ConClusions: Results 
indicate a good safety profile with respect to cardiovascular risk for DRSP/estra-
diol. Serious cardiovascular events occur less frequently in DRSP/estradiol users 
compared to users of other continuous-combined HRT. This specificAS approach 
proved to be a successful approach with high long term follow-up success and 
high validity of safety results.
INDIvIDUAl’S HEAlTH – Cost Studies
PIH7
bUDgET IMPACT OF HPv16/18 gENOTyPINg TESTS FOR THE MANAgEMENT OF 
NON-CONCORDANT COTESTINg CERvICAl CANCER SCREENINg RESUlTS: A 
UNITED STATES PAyER PERSPECTIvE
Huang J.1, Hertz D.2, Conner A.2, Garfield S.2
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2GfK Bridgehead, Wayland, MA, USA
objeCtives: To assess the impact of managing women with high-risk HPV positive 
and Pap negative results (hrHPV+/Pap-) attending cervical cancer (CxCa) screening 
with a Pap and HPV test (co-testing). The strategies tested reflect different options 
available if a hrHPV test versus a hrHPV including 16/18 genotyping (3-in-1 test) 
is used upon initial screen. Methods: A budget-impact model was developed, 
from a US payer perspective. Data from the ATHENA (Addressing THE Need for 
Advanced HPV Diagnostics) trial and published literature were used to populate 
the model. The scenarios tested include repeat co-testing in 12 months, reflex 
genotyping HPV16/18, or routine co-testing with genotyping results already avail-
able from a 3-in-1 test for triage to colposcopy. The model examined the annual 
cost of testing and treatment for cervical intraepithelial neoplasia grade 2 or worse 
(≥ CIN2) and the cost of patients loss-to-follow-up. For a hypothetical population 
of women between ages 30 to 69, it assumes 48.5% were co-tested within the CxCa 
screening program every 3 years. Of those, 6.7% of women receive hrHPV+/Pap- 
results. Test performance was modeled as equivalent for both genotyping sce-
narios. Results: In the hrHPV+/Pap- population, the cost of ≥ CIN2 cases detected 
and treated for each testing strategy and the rate of progression to invasive CxCa 
per 10,000 hrHPV+/Pap- results was $10,530/9.2 (repeat co-testing at 12 months), 
$8,500/2.6 (reflex HPV16/18) and $7,278/2.6 (routine co-testing with 3-in-1 test). 
Using HPV16/18 genotyping to manage discordant co-testing results increased 
≥ CIN2 cases detected and prevented disease progression. Compared to other HPV 
tests that require reflex genotyping, screening with a 3-in-1 test reduced the cost 
of follow-up by 17% annually. ConClusions: Genotyping for HPV 16/18 improved 
the detection of ≥ CIN2 cases over repeat co-testing in 12 months; moreover, com-
pared to other HPV testing strategies, the 3-in-1 test reduced costs and may be a 
prudent screening alternative.
PIH8
ECONOMIC IMPACT OF THE USE OF AN AbSORbAblE ADHESION bARRIER IN 
PREvENTINg ADHESIONS FOllOwINg OPEN gyNECOlOgIC SURgERIES
Roy S.1, Carlton R.2, Clark R.S.2, Migliaccio-Walle K.2
1Johnson & Johnson Global Surgery Group, Somerville, NJ, USA, 2Xcenda, LLC, Palm Harbor, FL, 
USA
objeCtives: Abdominal adhesions are common after gynecologic surgeries, 
often resulting in complications such as bowel obstruction and chronic pain, 
which may lead to increased length of stay and more frequent readmissions. 
GYNECARE INTERCEED® Absorbable Adhesion Barrier is associated with fewer 
adhesion-related outcomes compared to surgeries without an adhesion-barrier. 
This analysis assesses the budget impact of GYNECARE INTERCEED® for reduc-
ing the incidence of postoperative adhesions in open surgical gynecologic pro-
cedures. Methods: A model was constructed to evaluate the budget impact to 
hospitals of adopting GYNECARE INTERCEED® for women undergoing open surgical 
gynecologic procedures. C-section surgery, hysterectomy, myomectomy, ovarian 
surgery, tubal surgery, and endometriosis surgery were modeled with and without 
the use of GYNECARE INTERCEED®. Incremental GYNECARE INTERCEED® material 
costs, medical costs arising from complications, and adhesion-related readmis-
sions were considered. GYNECARE INTERCEED® use was assumed in 50% of all 
procedures. Budget impact was reported over a 3-year period from a US hospital 
perspective (US$2013). Results: Assuming 100 gynecologic surgeries of each type 
and an average of one GYNECARE INTERCEED® sheet per surgery, a net savings 
of $439,975 with GYNECARE INTERCEED® over 3 years is estimated. GYNECARE 
INTERCEED® use resulted in 80 fewer patient cases developing adhesions. Although 
the use of GYNECARE INTERCEED® added $91,500 in material costs, this was com-
pletely offset by the reduction in complication costs ($230,766 savings) and fewer 
adhesion-related readmissions ($300,709 savings). By preventing adhesion-related 
complications, GYNECARE INTERCEED® prevented over 206 additional hospital days 
for patients. ConClusions: This analysis represents the first economic assess-
ment of GYNECARE INTERCEED® use in open gynecologic surgeries that incorpo-
rates the cost of the adhesion barrier, complications, and readmissions. Adoption 
of GYNECARE INTERCEED® absorbable adhesion barrier for appropriate gynecologic 
surgeries would likely result in significant savings for hospitals which would largely 
be driven by clinical patient benefits in terms of fewer complications and adhesion-
related readmissions.
PIH9
bUDgET IMPACT OF DIENOgEST IN TREATINg ENDOMETRIOSIS ASSOCIATED 
PElvIC PAIN IN bRAzIl: A PUblIC PERSPECTIvE ANAlySIS
Ferracini M., Nakada C.P.
Bayer Healthcare Brazil, São Paulo, Brazil
objeCtives: Evaluate the budget impact to the public health care system in 
Brazil after introducing dienogest (2 mg) as a treatment option in detriment of 
GnRH analogues (GnRHa) for patients with endometriosis-associated pelvic pain 
(EAPP). Methods: The analysis was conducted from the public perspective over 
a five-year time horizon. The budget impact model (BIM) specifically considered 
comparison to UAE (pregnancies: 3.44, 95%CI 1.18- 10.03; live-births: 3.02, 95%CI 
1.00- 9.09). ConClusions: LUAO is less effective than UAE and MYO in the treat-
ment of symptomatic fibroids for women who want to preserve their uterus. The 
choice between UAE and MYO should be based on individuals’ short and long-
term expectations.
PIH3
META-ANAlySIS OF bCg vACCINE EFFICACy FOR INFANTS IN IRElAND
Schmitz S.1, Usher C.2, Adams R.2, Kieran J.1, Barry M.2, Walsh C.1
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland
objeCtives: BCG vaccination policy is greatly debated. An important issue for coun-
tries using the vaccine is to try and estimate any influence it has on the tuberculosis 
(TB) incidence in their population. The aim of this study is to estimate the effective-
ness of the BCG vaccine in infants in Ireland. Methods: We searched PubMed and 
Embase for studies assessing a relative reduction in TB events after vaccination 
in infants. Studies meeting relevant inclusion and exclusion criteria were sought. 
Observational data from Ireland was combined with raw data from studies identified 
in the literature in a random-effects meta-analysis model to estimate the relative 
risk (RR) of vaccine efficacy against pulmonary TB, extra-pulmonary TB (EPTB), TB 
meningitis and TB deaths. Results: Two meta-analyses were found. The first meta-
analysis reviewed identified 5 randomised control trials and 11 case control studies 
against pulmonary TB (Trials 0.26 95% CI 0.17, 0.38; Cases 0.48 95% CI 0.37, 0.62) 
and TB deaths (Trials 0.35 95% CI 0.14, 0.88). The second meta-analysis identified a 
further 7 case-control studies and evaluated BCG efficacy against EPTB (0.23 95%CI 
0.13, 0.42] and TB meningitis (0.27 95%CI 0.21, 0.33). Estimates from observational 
data from Ireland for pulmonary TB were (0.14, 95%CI 0.09, 0.20), EPTB (0.11, 95%CI 
0.05, 0.21), TB meningitis (0.17, 95%CI 0.04, 0.75) and TB deaths (0.13, 95%CI 0.00, 6.37). 
Pooled RR estimates from Irish data and international estimates show a significant 
reduction in TB cases: Pulmonary TB: 0.26 (95% CI: 0.13, 0.54), EPTB: 0.16 (95%CI: 
0.08, 0.34), TB meningitis: 0.27 (95%CI: 0.21, 0.34) and TB deaths: 0.33 (95%CI: 0.14, 
0.81). ConClusions: This meta-analysis of local observational data with interna-
tional trial data indicates that vaccination of infants with the BCG vaccine reduces 
the risk of pulmonary TB, EPTB, TB meningitis and TB deaths.
PIH4
CO-ADMINISTRATION OF ANTIPSyCHOTICS AND ANTI-DEMENTIA DRUgS IN 
AUSTRIA
Hinteregger M.1, Füzi J.2, Reichardt B.3
1Main Association of Austrian Social Security Institutions, Vienna, Austria, 2Sickness Fund 
Burgenland, Eisenstadt, Austria, 3Sickness Fund Burgenland, Eisenstadt, Burgenland, Austria
objeCtives: The use of antipsychotics for people with dementia is regarded as 
problematic, causing cerebrovascular side effects and increasing mortality. In 
some countries, health-policy makers have already addressed a need for action 
to reduce the prescription of antipsychotics in dementia. The main goal of the 
analysis is to determine the extent of co-medication of antipsychotics for patients 
with medically-treated dementia in Austria, stratified by age and sex. Methods: 
Provided in a pseudonymised manner, the data comprise all filled prescriptions of 
cholinesterase inhibitors and memantine in the years 2011 and 2012 at the expense 
of the 13 major Austrian health insurance funds, covering more than 97% of the 
Austrian population. Additionally, antipsychotic medication of the involved patient 
pseudonyms is included, as well as age, sex and – where occurred – date of death. 
For the analysis, the overlapping time frame is relevant, i.e. when both substance 
groups were consumed. Descriptive statistics are used to capture the extent and 
variability of a co-medication of these two substance groups. Results: Starting 
with 72,549 patients included in the data (66% female), 31,605 (43.6%) were concur-
rently being prescribed antipsychotics to their anti-dementia drugs. The median 
for the overlapping time frame is 294 days, for anti-dementia prescriptions it is 
eleven and for antipsychotics it is seven. Age is a factor for increasing antipsy-
chotic medication. Considering demography, there are no remarkable differences 
between men and women. ConClusions: Our data demonstrate that the use of 
antipsychotics in dementia is notably common in Austria, with a high prevalence 
as well as a tendency to long-term use. The results reflect the prescription reality 
and can be used as a solid basis for discussions, possible actions and evaluations 
about antipsychotics in dementia in the Austrian health system.
PIH6
ASSESSINg PRODUCT SAFETy vIA PATIENT bASED ACTIvE SURvEIllANCE (AS): 
A STUDy IN 30.000 wOMEN USINg HORMONE REPlACEMENT THERAPy (HRT)
Heinemann K.1, Bardenheuer K.1, Potthoff P.2
1ZEG-Berlin, Berlin, Germany, 2Kantar Health GmbH, München, Germany
objeCtives: The novel progestin drospirenone (DRSP) has antimineralocorticoid 
properties with potentially beneficial as well as unfavorable effects on cardiovas-
cular outcomes compared to other progestins. A patient based AS study was set 
up to compare incidence rates of serious adverse events – in particular cardiovas-
cular outcomes - in users of oral continuous combined preparations. Methods: 
Prospective, controlled cohort study (2002-2011) with three arms: women using 
1) DRSP/estradiol; 2) other oral continuous-combined HRT (occHRT); and 3) all 
other oral HRTs. The study population included women aged 40 or older in seven 
European countries starting or switching to an oral HRT at time of inclusion in the 
study. Outcomes were collected from the patients and validated by the treating 
physicians. A multifaceted 4-level follow-up procedure was to ensure low loss to 
follow-up rates. The analysis is based on Cox regression models comparing the 
cohorts. Results: A total of 30,597 users of oral HRT preparations – reflecting 
more than 101,000 WY of observation – were recruited by 1,052 centers. Incidence 
rates of DRSP/estradiol and low-dose occHRT for venous thromboembolic events 
were 17.5 (95% CI: 11.2-26.0) and 18.2 (95% CI: 11.9-26.6) per 10,000 WY, respectively. 
The respective incidence rates for arterial thromboembolism were 10.9 (95% CI: 
6.1-18.0) and 29.8 (95% CI: 24.1-36.4 ) per 10,000 WY with a hazard ratio adjusted 
for age, BMI, hypertension, region, family history of fatal ATE, diabetes, user status 
